Major Depression Disorder
12
6
6
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Home tDCS for the Treatment of Major Depression.
Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression
Digital Interventions for Relapse Prevention in Adolescence
Neuromodulation and Attention Deficits in MDD
Molecular Signatures of TMS Response in Treatment-Resistant Depression
The OBSERVE Protocol
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder
Predictive Effect of Neuroinflammatory Factors of the MECT in Treatment of Senile Depression
Somatic Comorbidities in Psychiatric Patients
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder